Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Cecilia Dallavalle, … , Carlo V. Catapano, Giuseppina M. Carbone
Cecilia Dallavalle, … , Carlo V. Catapano, Giuseppina M. Carbone
Published December 1, 2016; First published November 7, 2016
Citation Information: J Clin Invest. 2016;126(12):4585-4602. https://doi.org/10.1172/JCI86505.
View: Text | PDF
Categories: Research Article Oncology

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression

  • Text
  • PDF
Abstract

Mutations and deletions in components of ubiquitin ligase complexes that lead to alterations in protein turnover are important mechanisms in driving tumorigenesis. Here we describe an alternative mechanism involving upregulation of the microRNA miR-424 that leads to impaired ubiquitination and degradation of oncogenic transcription factors in prostate cancers. We found that miR-424 targets the E3 ubiquitin ligase COP1 and identified STAT3 as a key substrate of COP1 in promoting tumorigenic and cancer stem-like properties in prostate epithelial cells. Altered protein turnover due to impaired COP1 function led to accumulation and enhanced basal and cytokine-induced activity of STAT3. We further determined that loss of the ETS factor ESE3/EHF is the initial event that triggers the deregulation of the miR-424/COP1/STAT3 axis. COP1 silencing and STAT3 activation were effectively reverted by blocking of miR-424, suggesting a possible strategy to attack this key node of tumorigenesis in ESE3/EHF–deficient tumors. These results establish miR-424 as an oncogenic effector linked to noncanonical activation of STAT3 and as a potential therapeutic target.

Authors

Cecilia Dallavalle, Domenico Albino, Gianluca Civenni, Jessica Merulla, Paola Ostano, Maurizia Mello-Grand, Simona Rossi, Marco Losa, Gioacchino D’Ambrosio, Fausto Sessa, George N. Thalmann, Ramon Garcia-Escudero, Andrea Zitella, Giovanna Chiorino, Carlo V. Catapano, Giuseppina M. Carbone

×

Figure 8

miR-424 promotes tumor initiation recapitulating in vivo miR-424/COP1/STAT3 axis.

Options: View larger image (or click on image) Download as PowerPoint
miR-424 promotes tumor initiation recapitulating in vivo miR-424/COP1/ST...
(A–C) IB of COP1, STAT3, and p-STAT3 (A), colony formation in soft agar (B), and SFE (C) in RWPE1 cells following cotransfection with miR-424 or Ctr and siRNA targeting STAT3 (siSTAT3) or control siRNA (siGL3). (D–F) IB of COP1, STAT3, and p-STAT3 (D), colony formation in soft agar (E), and SFE (F) in RWPE1 cells 48 hours after transfection with miR-424 or Ctr and treatment with 5 μM NVP or DMSO for 16 hours. (G and H) Tumor growth (G), tumor weight (H), and representative images of tumors (bottom) of subcutaneous xenografts in nude mice, from RWPE1 cells transfected with miR-424 (n = 4) or Ctr (n = 4). (I) H&E and IHC stain and scores (percentage of positive cells) of STAT3, p-STAT3, COP1, and Ki67 stain of control and miR-424 induced xenografts described above. Scale bars: 10 μm. (J) Schematic of the experimental plan (left) and tumor volume (right). *P < 0.05; **P < 0.01.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts